Home
About Us
Help and Support
Subscribe
Company Analyst
Financial Analyst
Pipeline Analyst
Archives
Tools
Log In
Print this
galeterone (TOK-001)
print preview
bookmark
share with colleague
General Information
Company
Tokai Pharmaceuticals Inc.
Description
Selective androgen receptor modulator (SARM) and cytochrome P450 17 alpha-hydroxylase/C17,20 lyase (CYP17) inhibitor
Molecular Target
Cytochrome P450 17 alpha-hydroxylase/C17, 20 lyase (CYP17)
;
Androgen receptor
Mechanism of Action
Androgen receptor antagonist; Cytochrome P450 17alpha-hydroxylase/C17,20 lyase (CYP17) inhibitor
Latest Stage of Development
Phase II
Indication
Prostate cancer
Partner
Product Summary: Number of Indications in each Phase of Development by Disease Category
More
Product Details
Archive Items are loading
Set Email Alert
dummy